Therefore, the magnitude in the COVID‐19 group was significantly elevated compared with that in the V2/V3 group and the IV/VI group, which showed a median of 0.12% (range 0.02–4.97%) and 0.24% (range 0.02–4.17%) IFN‐γ+ cells per peptide, respectively (COVID‐19 vs. V2/V3, P < 0.0001; COVID‐19 vs. IV/VI, P < 0.0001; and V2/V3 vs. IV/VI, P = 0.0031). The gene discussed is IFNG; the disease is COVID-19.